[go: up one dir, main page]

MA35405B1 - Composition pharmaceutique contenant un dérivé d'amide inhibant la croissance des cellules cancéreuses et un lubrifiant à base d'un sel non métallique - Google Patents

Composition pharmaceutique contenant un dérivé d'amide inhibant la croissance des cellules cancéreuses et un lubrifiant à base d'un sel non métallique

Info

Publication number
MA35405B1
MA35405B1 MA36642A MA36642A MA35405B1 MA 35405 B1 MA35405 B1 MA 35405B1 MA 36642 A MA36642 A MA 36642A MA 36642 A MA36642 A MA 36642A MA 35405 B1 MA35405 B1 MA 35405B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
composition containing
amide derivative
growth
metallic salt
Prior art date
Application number
MA36642A
Other languages
English (en)
Inventor
Yong Il Kim
Kyeong Soo Kim
Jin Cheul Kim
Yo Han Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA35405B1 publication Critical patent/MA35405B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/604—Polycarboxylic acid esters, the acid moiety containing more than two carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Charge And Discharge Circuits For Batteries Or The Like (AREA)

Abstract

La présente invention concerne une composition pharmaceutique contenant un dérivé d'amide ou un sel pharmaceutiquement acceptable de celui-ci et un lubrifiant à base d'un sel non métallique. La composition pharmaceutique peut être utilisée comme inhibiteur efficace de la croissance des cellules cancéreuses, car elle est très stable pendant son stockage et sa qualité ne change pas au cours du temps.
MA36642A 2011-06-07 2014-01-03 Composition pharmaceutique contenant un dérivé d'amide inhibant la croissance des cellules cancéreuses et un lubrifiant à base d'un sel non métallique MA35405B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110054685A KR101317809B1 (ko) 2011-06-07 2011-06-07 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
PCT/KR2012/003970 WO2012169733A1 (fr) 2011-06-07 2012-05-18 Composition pharmaceutique contenant un dérivé d'amide inhibant la croissance des cellules cancéreuses et un lubrifiant à base d'un sel non métallique

Publications (1)

Publication Number Publication Date
MA35405B1 true MA35405B1 (fr) 2014-09-01

Family

ID=47296259

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36642A MA35405B1 (fr) 2011-06-07 2014-01-03 Composition pharmaceutique contenant un dérivé d'amide inhibant la croissance des cellules cancéreuses et un lubrifiant à base d'un sel non métallique

Country Status (26)

Country Link
US (2) US9731022B2 (fr)
EP (1) EP2718282B1 (fr)
JP (1) JP6030643B2 (fr)
KR (1) KR101317809B1 (fr)
CN (1) CN103596940B (fr)
AR (1) AR086851A1 (fr)
AU (1) AU2012267642C1 (fr)
BR (1) BR112013030456B1 (fr)
CA (2) CA3053181A1 (fr)
CL (1) CL2013003513A1 (fr)
CO (1) CO6852070A2 (fr)
DK (1) DK2718282T3 (fr)
EC (1) ECSP14013121A (fr)
ES (1) ES2625268T3 (fr)
IL (1) IL229739B (fr)
MA (1) MA35405B1 (fr)
MX (3) MX361129B (fr)
MY (1) MY166949A (fr)
PE (1) PE20141040A1 (fr)
PH (1) PH12013502542B1 (fr)
PT (1) PT2718282T (fr)
RU (1) RU2632099C2 (fr)
TW (1) TWI617307B (fr)
UA (1) UA112545C2 (fr)
WO (1) WO2012169733A1 (fr)
ZA (1) ZA201400051B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
EP2878453A1 (fr) 2013-11-28 2015-06-03 Authentic Vision GmbH Marquage d'objets pour l'authentification optique et son procédé de fabrication
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101669240B1 (ko) * 2015-03-12 2016-10-25 아주대학교산학협력단 테노포비어 디소프록실 유리염기를 포함하는 정제 및 이의 제조방법
JP6585193B2 (ja) * 2015-12-28 2019-10-02 沢井製薬株式会社 ゲフィチニブ含有錠剤
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN117599061A (zh) 2016-11-17 2024-02-27 得克萨斯州大学系统董事会 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物
EP3773551B1 (fr) * 2018-03-27 2024-10-16 Board of Regents, The University of Texas System Composés ayant une activité antitumorale contre des cellules cancéreuses portant des mutations her2 exon 19
KR20220080044A (ko) 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
MX2021002876A (es) * 2018-09-14 2021-06-04 Spectrum Pharmaceuticals Inc Kits y metodos para tratar canceres.
SG11202109531UA (en) * 2019-03-29 2021-09-29 Univ Texas Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
KR102254307B1 (ko) * 2019-04-03 2021-05-21 위더스제약주식회사 보관 안정성이 향상된 에페리손 약제학적 조성물
KR102812658B1 (ko) * 2019-10-24 2025-05-26 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
EP4048234A4 (fr) 2019-10-24 2023-11-29 Hanmi Pharm. Co., Ltd. Préparation pharmaceutique comprenant un dérivé amide inhibant la croissance d'une cellule cancéreuse et produit pharmaceutique le contenant

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02275891A (ja) * 1988-12-29 1990-11-09 Tsumura & Co 新規な複核白金錯体および該錯体を有効成分とする抗腫瘍剤
SK282183B6 (sk) 1994-08-23 2001-11-06 Smithkline Beecham Plc Farmaceutický prostriedok
KR980008219A (ko) 1996-07-16 1998-04-30 김상응 안정화된 주사제용 약제학적 조성물
KR980008219U (ko) 1996-07-31 1998-04-30 배순훈 세탁기의 구동모터 냉각팬
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP3687025B2 (ja) 1998-06-04 2005-08-24 東和薬品株式会社 安定なマレイン酸エナラプリル錠剤
IL148576A0 (en) 1999-09-21 2002-09-12 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU2003226705B2 (en) 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
EP1670782B1 (fr) 2003-09-19 2007-02-14 AstraZeneca AB Derives de quinazoline
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
CA2540008A1 (fr) 2003-09-25 2005-04-07 Astrazeneca Ab Derives de quinazoline
DE10345875A1 (de) 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
JPWO2005090332A1 (ja) 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
WO2007023073A2 (fr) 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Heterocycles bicycliques, produits pharmaceutiques contenant ces composes, leur utilisation et procede pour les preparer
BRPI0619603A2 (pt) 2005-12-12 2011-10-11 Boehringer Ingelheim Int heterociclos bicìclicos, sais fisiologicamante compatìveis, medicamentos que contêm esses compostos, bem como uso e processos para produção dos heterociclos bicìclicos
PT1847258E (pt) 2006-04-13 2010-06-22 Riemser Specialty Production G Glicéridos parciais como lubrificante para composições farmacêuticas que contêm derivados de tieno[3,2-c]piridina
WO2007118854A1 (fr) 2006-04-13 2007-10-25 Euro-Celtique S.A. Composés à base de benzènesulfonamide et leur utilisation
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
CN101778625A (zh) 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
MY144136A (en) 2009-04-20 2011-08-10 Univ Sains Malaysia Throttle and brake lock
AU2010273319B2 (en) * 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
MX2012008153A (es) * 2010-01-12 2012-11-06 Nestec Sa Metodos para predecir la respuesta a terapia de cancer de mama triple negativo.
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체

Also Published As

Publication number Publication date
AU2012267642C1 (en) 2017-11-16
US9931406B2 (en) 2018-04-03
AR086851A1 (es) 2014-01-29
PH12013502542A1 (en) 2014-02-10
EP2718282B1 (fr) 2017-03-15
BR112013030456A2 (pt) 2016-09-27
US9731022B2 (en) 2017-08-15
US20140112962A1 (en) 2014-04-24
MX2013013997A (es) 2014-06-23
PH12013502542B1 (en) 2018-07-11
IL229739B (en) 2018-01-31
ZA201400051B (en) 2015-04-29
MY166949A (en) 2018-07-25
MX361129B (es) 2018-11-28
RU2632099C2 (ru) 2017-10-02
US20170340744A1 (en) 2017-11-30
AU2012267642B2 (en) 2017-04-20
EP2718282A4 (fr) 2015-04-15
CL2013003513A1 (es) 2014-09-26
PE20141040A1 (es) 2014-09-08
KR101317809B1 (ko) 2013-10-16
CA2837703A1 (fr) 2012-12-13
WO2012169733A1 (fr) 2012-12-13
CO6852070A2 (es) 2014-01-30
IL229739A0 (en) 2014-01-30
NZ619606A (en) 2015-07-31
ECSP14013121A (es) 2014-02-28
JP6030643B2 (ja) 2016-11-24
JP2014516082A (ja) 2014-07-07
KR20120135777A (ko) 2012-12-17
CN103596940A (zh) 2014-02-19
UA112545C2 (uk) 2016-09-26
AU2012267642A1 (en) 2014-01-30
TWI617307B (zh) 2018-03-11
MX2021005494A (es) 2022-06-08
CN103596940B (zh) 2017-09-12
CA2837703C (fr) 2019-09-24
BR112013030456B1 (pt) 2022-08-02
PT2718282T (pt) 2017-05-25
EP2718282A1 (fr) 2014-04-16
ES2625268T3 (es) 2017-07-19
TW201302201A (zh) 2013-01-16
DK2718282T3 (en) 2017-05-22
RU2013158858A (ru) 2015-07-20
MX382470B (es) 2025-03-13
CA3053181A1 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
MA35405B1 (fr) Composition pharmaceutique contenant un dérivé d'amide inhibant la croissance des cellules cancéreuses et un lubrifiant à base d'un sel non métallique
RU2370495C2 (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
MA34368B1 (fr) Composition pharmaceutique comprenant un dérivé d'amide ou son sel pharmaceutiquement acceptable
PE20190977A1 (es) Compuestos de 7-feniletilamino-4h-pirimido [4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e ihd2 mutantes
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
EA200801784A1 (ru) Ингибиторы е1 активирующих ферментов
CL2012001328A1 (es) Compuestos derivados de (4,5,6,7-tetrahidro-1h-indazol-3-il)-1h-indol, inhibidores de itk; composicion farmaceutica; utiles en el tratamiento de enfermedades inflamatorias, tales como artritis reumatoidea, alergias, enfermedades autoinmunes, entre otras.
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
TW200740761A (en) Histone deacetylase inhibitors
MA34457B1 (fr) Combinaison d'un composé glyt1 avec des agents antipsychotiques
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
MX2009006228A (es) Inhibidores de aspartil proteasa.
ECSP078003A (es) Inhibidores de aspartil proteasas
UY32631A (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparación y su aplicación en terapéutica.
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
EA201200474A1 (ru) Гетероциклические производные в качестве ингибиторов глутаминилциклазы
MA34249B1 (fr) Utilisation de stimulateurs de la sgc, d'activateurs de la sgc, seuls et en association avec des inhibiteurs de la pde5 en vue du traitement de la sclérodermie systémique
MA38238A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201390412A1 (ru) Стабилизированная композиция такролимуса
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
AR062133A1 (es) Composiciones de combustible
NZ594108A (en) Benzimidazole compounds useful as inhibitors of Histone Deacetylase (HDAC)